Scilex Holding Past Earnings Performance
Past criteria checks 0/6
Scilex Holding has been growing earnings at an average annual rate of 4.7%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 22.5% per year.
Key information
4.7%
Earnings growth rate
-5.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 22.5% |
| Return on equity | n/a |
| Net Margin | -357.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks
Apr 24
Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues
Feb 28Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)
Dec 21Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings
May 06Revenue & Expenses BreakdownBeta
How Scilex Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 47 | -167 | 120 | 13 |
| 30 Sep 23 | 45 | -163 | 120 | 13 |
| 30 Jun 23 | 46 | -54 | 95 | 10 |
| 31 Mar 23 | 42 | -45 | 83 | 9 |
| 31 Dec 22 | 38 | -23 | 65 | 9 |
| 30 Sep 22 | 34 | -47 | 56 | 9 |
| 30 Jun 22 | 31 | -81 | 51 | 9 |
| 31 Mar 22 | 33 | -78 | 49 | 9 |
| 31 Dec 21 | 31 | -88 | 51 | 9 |
| 31 Dec 20 | 24 | -48 | 43 | 10 |
| 31 Dec 19 | 21 | -179 | 65 | 10 |
Quality Earnings: SCLX is currently unprofitable.
Growing Profit Margin: SCLX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCLX is unprofitable, but has reduced losses over the past 5 years at a rate of 4.7% per year.
Accelerating Growth: Unable to compare SCLX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCLX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: SCLX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.